Introduction {#section1-2192568217710911}
============

Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death in men in the United States.^[@bibr1-2192568217710911]^ Almost 35% of prostate cancer patients have metastatic disease at time of death.^[@bibr2-2192568217710911]^ Osseous metastases are the most common,^[@bibr3-2192568217710911],[@bibr4-2192568217710911]^ occurring in more than 80% of patients with hormone-refractory prostate cancer,^[@bibr5-2192568217710911]^ with the spine being the most common site.^[@bibr6-2192568217710911][@bibr7-2192568217710911]--[@bibr8-2192568217710911]^ Roughly one third of prostate metastases to the spine become symptomatic^[@bibr4-2192568217710911]^ from spinal cord compression or mechanical instability.^[@bibr9-2192568217710911]^

The goal of treatment is to improve quality of life through symptomatic relief.^[@bibr10-2192568217710911][@bibr11-2192568217710911]--[@bibr12-2192568217710911]^ Since the study by Patchell et al^[@bibr12-2192568217710911]^ was published, the surgical treatment of spinal metastases has been guided by the superiority of direct surgical decompression and radiation to radiation alone in the treatment of symptomatic spinal cord compression. This solitary Level 1 study and 3 Class II studies demonstrated increased survival and ambulatory function in mixed-histology series^[@bibr11-2192568217710911],[@bibr13-2192568217710911],[@bibr14-2192568217710911]^ and support the surgical intervention in a broad range of spinal metastases.^[@bibr12-2192568217710911],[@bibr15-2192568217710911][@bibr16-2192568217710911][@bibr17-2192568217710911]--[@bibr18-2192568217710911]^ However, studies focusing on prostate-specific data point to better decisions regarding interventions.

Conforming to PRISMA^[@bibr19-2192568217710911]^ guidelines, this article systematically reviews the literature to determine the indications and outcomes of the surgical treatment of metastatic prostate cancer of the spine (MPCS) to address key clinical questions:**Question 1:** Describe the survival and functional outcomes of surgery or vertebral augmentation.**Question 2:**Determine whether overall tumor burden, Gleason score, preoperative functional markers, and hormonal naivety favor operative intervention.**Question 3:** Establish whether clinical outcomes vary with the evolution of operative techniques.

Methods {#section2-2192568217710911}
=======

Electronic Literature Search {#section3-2192568217710911}
----------------------------

A comprehensive search of major databases (Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Database of Systematic Reviews, Scopus) from inception to October 2013 was conducted by a librarian and the study's principal investigator using controlled vocabulary and keywords to search for studies explicitly designed to evaluate patient-specific outcomes of surgery or vertebral augmentation for MPCS. The actual strategy is available from the corresponding author on request. Nonhuman studies, case reports, meeting abstracts, review articles, and editorials were excluded. Mixed tumor series were reviewed to extract disease-specific information. The patient-intervention-control-outcome (PICO) summary of inclusion and exclusion is described in [Table 1](#table1-2192568217710911){ref-type="table"}.

###### 

Selection Criteria.

![](10.1177_2192568217710911-table1)

                 Inclusion                                                                                                              Exclusion
  -------------- ---------------------------------------------------------------------------------------------------------------------- -----------------------------------------------
  Patient        Adult patients with surgically treated prostate metastasis to the spine                                                No surgical treatment
                                                                                                                                        Unknown diagnosis
  Intervention   Questions 1/2: Operative treatment of PM                                                                               Revision surgery
                 Question 3: Decompression ± stabilization of PM specifically targeting area of compression ("Patchell" intervention)   
  Control        Questions 1/2: None                                                                                                    
                 Question 3: Laminectomy ±- stabilization                                                                               
  Outcomes       Survival                                                                                                               
                 Functional                                                                                                             
                 Ambulation                                                                                                             
                 Continence                                                                                                             
  Study type     Questions 1/2: Case series specifically designed to evaluate treatment of PM                                           Case reports
                 Question 3: RCTs and nonrandomized comparative studies                                                                 Biomechanical studies
                                                                                                                                        Studies with n \< 5
                                                                                                                                        Surgical case series not designed to treat PM

Abbreviations: PM, prostate metastasis; RCTs, randomized controlled trials.

Data Extraction {#section4-2192568217710911}
---------------

Full versions of the articles meeting the inclusion criteria were reviewed. Data extracted included study design, demographics, presentation, treatment, and outcomes, including postoperative survival and neurologic parameters (motor weakness, sensory dysfunction, ambulatory status, and bladder continence).

Study Quality and Overall Strength of Evidence {#section5-2192568217710911}
----------------------------------------------

Class-of-evidence (CoE) ratings were assigned to each article by 2 reviewers (MJC, DMS) accounting for methodological quality and sources of bias based on recommendations of the Agency of Healthcare Research and Quality (AHRQ).^[@bibr20-2192568217710911][@bibr21-2192568217710911][@bibr22-2192568217710911]--[@bibr23-2192568217710911]^

The overall strength of the body of evidence was based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group^[@bibr24-2192568217710911][@bibr25-2192568217710911]--[@bibr26-2192568217710911]^ and AHRQ^[@bibr20-2192568217710911],[@bibr22-2192568217710911]^ and is a measure of our confidence that the effect size closely matches the true effect and is stable.^[@bibr27-2192568217710911]^ The overall strength of evidence is considered "Strong" if the majority of studies were Class I or II and indicates that the true effect lies close to the estimated effect. It is considered "Weak" if the majority of studies were Class III or IV and indicates that the true effect may be very different from the estimated effect. A rating of "Insufficient" indicates there was too little evidence to estimate an effect. Overall strength was downgraded (inconsistent results, indirect evidence, imprecise estimates) or upgraded (large magnitude of effect, dose-response gradient)^[@bibr27-2192568217710911]^ as warranted.

Clinical Recommendations and Consensus Statements {#section6-2192568217710911}
-------------------------------------------------

Expert consensus opinion was obtained using a modified Delphi process involving subspecialty spine tumor surgeons at the AO Knowledge Forum Tumor section. Recommendations were made using the GRADE/AHRQ criteria that separates the strength of evidence from the strength of recommendations as described elsewhere.^[@bibr28-2192568217710911]^

Results {#section7-2192568217710911}
=======

Study Selection {#section8-2192568217710911}
---------------

The search yielded 360 relevant citations: 323 were excluded based on title/abstract, and 37 articles were reviewed. Fourteen were rejected because they had no outcomes of interest (9), did not involve postprocedural outcomes (2), or had \<5 cases (3). All 5 mixed-histology articles on vertebral augmentation were rejected as they had \<5 patients. Data sets overlapped in articles by Chaichana,^[@bibr29-2192568217710911]^ Ju,^[@bibr3-2192568217710911]^ and Crnalic^[@bibr5-2192568217710911],[@bibr30-2192568217710911]^; thus, the less comprehensive article was excluded. Of the remaining 16 studies, 10 studies^[@bibr31-2192568217710911][@bibr32-2192568217710911][@bibr33-2192568217710911][@bibr34-2192568217710911][@bibr35-2192568217710911][@bibr36-2192568217710911][@bibr37-2192568217710911][@bibr38-2192568217710911][@bibr39-2192568217710911]--[@bibr40-2192568217710911]^ contained only disease-specific data on overall survival. Thus, 16 articles^[@bibr3-2192568217710911][@bibr4-2192568217710911]--[@bibr5-2192568217710911],[@bibr31-2192568217710911][@bibr32-2192568217710911][@bibr33-2192568217710911][@bibr34-2192568217710911][@bibr35-2192568217710911][@bibr36-2192568217710911][@bibr37-2192568217710911][@bibr38-2192568217710911][@bibr39-2192568217710911][@bibr40-2192568217710911][@bibr41-2192568217710911][@bibr42-2192568217710911]--[@bibr43-2192568217710911]^ were studied for overall survival ([Figure 1A](#fig1-2192568217710911){ref-type="fig"}) and 6 studies^[@bibr3-2192568217710911][@bibr4-2192568217710911]--[@bibr5-2192568217710911],[@bibr41-2192568217710911][@bibr42-2192568217710911]--[@bibr43-2192568217710911]^ for all nonsurvival questions ([Figure 1B](#fig1-2192568217710911){ref-type="fig"}). These are summarized in [Table 2](#table2-2192568217710911){ref-type="table"}.

![Study selection for (A) survival and (B) remaining questions.](10.1177_2192568217710911-fig1){#fig1-2192568217710911}

###### 

Included Studies.

![](10.1177_2192568217710911-table2)

                                    Author (Year); Study Type                         Study Design                                      Inclusion                                       Exclusion                        Population of Interest                               Overall Survival Outcome   Level of Evidence
  --------------------------------- ------------------------------------------------- ------------------------------------------------- ----------------------------------------------- -------------------------------- ---------------------------------------------------- -------------------------- -------------------
  All questions                     Cereceda (2003); Case series                      Retrospective surgical case series for prostate   Spinal surgery for metastatic prostate cancer   Nonsurgically treated patients   n = 14                                               14 months (median)         IV
  Crnalic (2012); Case series       Retrospective all-modality series for prostate    Spinal surgery for metastatic prostate cancer     NR                                              n = 68                           16.8 months (weighted median); 30% alive at 1 year   IV                         
  Iacovou (1985); Case series       Retrospective surgical case series for prostate   Spinal surgery for metastatic prostate cancer     NR                                              n = 37                           NR                                                   IV                         
  Ju (2013); Case series            Retrospective surgical case series for prostate   Spinal surgery for metastatic prostate cancer     NR                                              n = 27                           10.2 months (median); 40% alive at 1 year            IV                         
  Shoskes (1989); Case series       Retrospective surgical case series for prostate   Spinal surgery for metastatic prostate cancer     NR                                              n = 28                           7 months (median); 9.5 months (mean)                 IV                         
  Williams (2009); Case series      Retrospective surgical case series for prostate   Spinal surgery for metastatic prostate cancer     NR                                              n = 44                           5.4 months (median)                                  IV                         
  Survival only                     Jansson (2006); Case series                       Retrospective mixed case series                   Spinal surgery for metastatic prostate cancer   All other tumors                 n = 114                                              36.3% alive at 1 year      IV
  Lau (2012); Case series           Retrospective mixed case series                   Spinal surgery for metastatic prostate cancer     All other tumors                                n = 8                            57.1% alive at 1 year                                IV                         
  Liskow (1986); Case series        Retrospective mixed case series                   Spinal surgery for metastatic prostate cancer     All other tumors                                n = 13                           46% alive at 1 year                                  IV                         
  Merrin (1976); Case series        Mixed case series                                 Spinal surgery for metastatic prostate cancer     All other tumors                                n = 10                           10.6 months (median)                                 IV                         
  Onimus (1996); Case series        Mixed case series                                 Spinal surgery for metastatic prostate cancer     All other tumors                                n = 12                           24 months (mean)                                     IV                         
  Pointillart (2011); Case series   Retrospective mixed case series                   Spinal surgery for metastatic prostate cancer     All other tumors                                n = 14                           6 months (median); 43% alive at 1 year               IV                         
  Sioutos (1995); Case series       Retrospective mixed case series                   Spinal surgery for metastatic prostate cancer     All other tumors                                n = 21                           11 months (median); 16 months (mean)                 IV                         
  Wang (2012); Case series          Retrospective mixed case series                   Spinal surgery for metastatic prostate cancer     All other tumors                                n = 107                          6.2 months (median)                                  IV                         
  Wibmer (2011); Case series        Retrospective mixed case series                   Spinal surgery for metastatic prostate cancer     All other tumors                                n = 23                           18.8 months (median)                                 IV                         
  Yang (2012); Case series          Retrospective mixed case series                   Spinal surgery for metastatic prostate cancer     All other tumors                                n = 13                           16 months (median)                                   IV                         
  Kyphoplasty                       No article met search criteria                                                                                                                                                                                                                                       

Abbreviation: NR, not recorded.

Survival {#section9-2192568217710911}
--------

Survival rates following intervention were recorded in 16 studies using various methods, often mixing hormone-naive and hormone-refractory patients ([Table 2](#table2-2192568217710911){ref-type="table"}). Four studies consistently demonstrate longer survival in hormone-naive patients ([Table 3](#table3-2192568217710911){ref-type="table"}).

###### 

Hormone Naivety.

![](10.1177_2192568217710911-table3)

  Study              Patients      Hormone-Naive Median Survival   Hormone-Refractory Median Survival
  ------------------ ------------- ------------------------------- ------------------------------------
  Crnalic            68            58.3 months; n = 15             5 months; n = 53
  Ju                 27            40.5 months^a^; n = 3           9.8 months; n = 24
  Williams           44                                            5.4 months; n = 44
  Jansson            114           1 year: 77% survival; n = 13    1 year: 26% survival; n = 101
  Weighted average   55.4 months   6.3 months                      

^a^Time to last known follow-up; all patients alive.

Other prostate-specific variables were reviewed for prognostic value. Elevated prostate-specific antigen (PSA) had a significant negative impact on survival in 2 studies.^[@bibr3-2192568217710911],[@bibr5-2192568217710911]^ Gleason score of ≥8 had a statistically significant difference in survival in one study^[@bibr4-2192568217710911]^ and not in another.^[@bibr3-2192568217710911]^ Overall tumor burden was reviewed. There was a statistically negative impact with visceral metastases^[@bibr4-2192568217710911],[@bibr5-2192568217710911]^ and lymph node involvement.^[@bibr4-2192568217710911]^ Ju noted no significant difference in complications for surgically treated patients with either visceral metastases or lymph node involvement.^[@bibr3-2192568217710911]^

Overall survival was affected by preoperative Karnofsky Performance Status (KPS) score. In the largest series, Crnalic noted a median survival of 22 months (n = 9) in patients with KPS ≥80, and 4.8 months (n = 44) in patients with KPS \<80.^[@bibr5-2192568217710911]^ Ju also found a statistically significant difference in survival.^[@bibr3-2192568217710911]^ Although a similar trend was seen in the Cereceda study (11.5 vs 8 months for KPS ≥ 80), this study was hampered by small numbers.^[@bibr41-2192568217710911]^

Pain and Functional Outcome {#section10-2192568217710911}
---------------------------

The goals of palliative surgery are the improvement or preservation of ambulation, bowel/bladder continence, and pain relief ([Table 4](#table4-2192568217710911){ref-type="table"}). Across 4 studies, 94% of patients maintained or improved strength at 1 month and 71% of patients were ambulatory. Of patients who were nonambulatory preoperatively, 55% regained ambulation. Spinal cord function outcomes were outlined in 3 studies by pre- and postoperative Frankel scores^[@bibr3-2192568217710911][@bibr4-2192568217710911]--[@bibr5-2192568217710911]^ ([Figure 2](#fig2-2192568217710911){ref-type="fig"}). Forty-three percent (52/122) had useful motor function (Grade D or E) preoperatively, increasing to 75% (92/122) postoperatively; 57% (40/70) without useful function regained it postoperatively. The number of patients improving 1 or more grades was 48% (59/122) while only 3% (4/122) worsened.

###### 

Other Factors With Statistically Significant Negative Effect on Survival.

![](10.1177_2192568217710911-table4)

  Study      PSA                      Gleason Score \>8       Visceral Metastases      Lymph Node Metastases   Karnofsky Performance Status Score \<80
  ---------- ------------------------ ----------------------- ------------------------ ----------------------- ----------------------------------------------------
  Crnalic    PSA \> 200                                       S: not defined                                   S: 22 vs 4.8 months
             S: 9 vs 4 months                                 Mets any                                         HR 4.66 (CI 1.9-11.44)
             HR 2.08 (CI 1.13-8.82)                           HR 2.52 (CI 1.35-4.70)                           
             N = 27                                                                                            
  Ju         PSA \> 150               S: not defined                                                           S: not defined
             S: 11.6 vs 6.7 months    ^a^HR 1.4 (CI 05.4.4)                                                    HR 3.3 (CI 1.1-9.9)
             HR 30 (CI 1-9.4)                                                                                  
             N = 24                                                                                            
  Williams                            S: not defined          S: not defined           S: not defined          
                                      *P* = .002              Mets \<5                 *P* = .04               
                                                              *P* = .001                                       
  Cerceda                                                                                                      S: 11.5 vs 8 months
                                                                                                               ^a^HR 0.72 (CI 0.15-3.4), calculated from raw data

Abbreviations: PSA, prostate-specific antigen; S, survival; HR, hazard ratio; CI, 95% confidence interval; Mets, number of metastases.

^a^Not statistically significant

![Frankel classification improvement at 1 month.](10.1177_2192568217710911-fig2){#fig2-2192568217710911}

Forty-nine percent of patients with bladder dysfunction related to spinal cord compression regained continence. Seventy-four percent of patients with preoperative pain noted improvement 1 month postoperatively based on studies by Cereceda et al^[@bibr41-2192568217710911]^ and Iacovou et al.^[@bibr42-2192568217710911]^ Both Ju and Williams noted a decrease in median narcotic use (40 mg/day to 10.7 mg/day morphine equivalents, and 10 mg/day to 4 mg/day)^[@bibr3-2192568217710911],[@bibr4-2192568217710911]^ and a decrease in steroid use (24 mg/day to 0 mg/day dexamethasone equivalents).^[@bibr3-2192568217710911]^

Surgical Outcome {#section11-2192568217710911}
----------------

Overall, 204 patients underwent a surgical procedure for prostate metastases to the spine in 5 studies.^[@bibr5-2192568217710911],[@bibr25-2192568217710911],[@bibr36-2192568217710911],[@bibr42-2192568217710911],[@bibr44-2192568217710911]^ Fifteen died in the perioperative period for an overall mortality of 7% (15/204). Three studies noted an overall complication rate of 32% (34/106)^[@bibr25-2192568217710911],[@bibr36-2192568217710911],[@bibr44-2192568217710911]^ and a major complication rate of 18% (19/106).^[@bibr25-2192568217710911],[@bibr36-2192568217710911],[@bibr44-2192568217710911]^

No study delineated surgical approach based on compressive pathology as advocated by Patchell et al.^[@bibr12-2192568217710911]^ It is possible that many patients underwent laminectomy in the setting of anterior compressive pathology. Anterior and combined anterior-posterior approaches were only noted in studies by Williams (55%)^[@bibr4-2192568217710911]^ and Ju (61%).^[@bibr3-2192568217710911]^ Patient numbers were low, and survival and functional outcomes based on surgical approach were not calculated; however, Ju noted no statistical difference in surgical complications.^[@bibr3-2192568217710911]^

Study Quality and Overall Strength of Literature {#section12-2192568217710911}
------------------------------------------------

All 12 articles were retrospective case series without control groups; thus, all had a baseline CoE of Level IV. Due to large, consistent effects, hormone-naivety and pain/functional outcome data were upgraded. Based on limited information and data, PSA, Gleason score, and metastatic disease data were downgraded. Based on the CoE and the quality of data, the overall strength of evidence is "Low" to "Insufficient" as outlined with each summary ([Table 5](#table5-2192568217710911){ref-type="table"}).

###### 

Functional Outcome.

![](10.1177_2192568217710911-table5)

  Study              Patients     \% Patients Pain Relief   \% Patients Maintain/Improve Strength   \% Patients Improved Strength   \% Total Patients Ambulating   \% Nonambulatory Patients Recovering Ambulation   \% Patients Recovering Continence
  ------------------ ------------ ------------------------- --------------------------------------- ------------------------------- ------------------------------ ------------------------------------------------- -----------------------------------
  Cereceda           14           66 (8/12)                 100 (12/12)                             42 (5/12)                       NR                             NR                                                NR
  Crnalic            68           NR                        100 (61/61)                             44 (27/61)                      59 (40/68)                     53 (32/60)                                        NR
  Iacuvou            37           77 (26/34)                NR                                      NR                              58 (20/34)                     48 (13/27)                                        50 (9/18)
  Ju                 27           NR                        93 (25/27)                              63 (17/27)                      81 (22/27)                     56 (5/9)                                          43 (3/7)
  Shokes             28           NR                        NR                                      NR                              82 (23/28)                     62 (8/13)                                         55 (6/11)
  Williams           44           NR                        89 (31/35)^a^                           54 (19/35)                      86 (36/42)                     67 (8/12)                                         45 (4/9)
  Weighted average   74 (34/46)   94 (99/106)               50 (68/135)                             71 (141/199)                    55 (66/121)                    49 (22/45)                                        

Abbreviation: NR, not recorded.

^a^Only includes surviving patients.

Clinical Recommendations and Consensus Statements {#section13-2192568217710911}
-------------------------------------------------

Although there is scant prostate-specific literature, the information gleaned from this systematic review, data from mixed tumor histology studies, and expert opinion were felt sufficient to provide clinical recommendations and consensus statements:Experts agreed that decompressive/reconstructive spinal surgery is beneficial in appropriately selected patients with MPCS. Although low in strength, evidence suggests that surgery improves quality of life, improves/preserves motor strength, ambulation, and bowel/bladder function with relatively low morbidity and mortality. (Level of recommendation: "Weak")No markers definitively precluded patients from surgical intervention. However:There was moderate evidence that hormone resistance has a large negative impact on overall postoperative survival. These patients had an average survival of over 6 months.In patients with MPCS, the extent of systemic metastases, medical comorbidities, and functional status must be considered when determining surgical candidacy.The evidence supporting the negative impact of hormone-refractory tumor status and low KPS on survival should be considered. These patients have a higher risk of limited postoperative survival; however, they may still be appropriate surgical candidates as each represents a unique combination of systemic considerations. (Level of recommendation: "Weak")In patients requiring spinal cord decompression, surgical options including instrumented spinal stabilization can be considered.Circumferential decompression may be indicated. Experts felt the blastic nature of most MPCS may lessen the need for corpectomy and stabilization compared with lytic histologies.In scenarios where laminectomy alone is indicated (direct or indirect decompression, stability is not in question, adjunctive treatments are available), a non-destabilizing laminectomy is performed. (Level of recommendation: "Weak")Based on expert opinion gleaned from the Delphi process, in patients with mechanical instability without neural compression, cement augmentation, percutaneous or open instrumented spinal stabilization represent potential treatment options. (Level of recommendation: "Weak")

Discussion {#section14-2192568217710911}
==========

Prostate cancer is a variable disease ranging from indolent to aggressive.^[@bibr45-2192568217710911]^ While localized disease may be cured with surgery and radiation, in 20% to 30% of patients the disease recurs.^[@bibr46-2192568217710911],[@bibr47-2192568217710911]^ Since androgens promote prostate cancer survival and growth,^[@bibr44-2192568217710911],[@bibr48-2192568217710911]^ androgen synthesis pathway ablation is the primary treatment for advanced disease.^[@bibr49-2192568217710911]^ Unfortunately, many patients develop androgen deprivation therapy insensitivity, also known as castration-resistant prostate cancer or hormone-refractory disease^[@bibr50-2192568217710911],[@bibr51-2192568217710911]^ with survival ranging from 1 to 2 years.^[@bibr47-2192568217710911]^ Up to 80% of patients with hormone-refractory prostate cancer develop spine metastases,^[@bibr5-2192568217710911]^ and up to one third of these will become symptomatic requiring intervention.^[@bibr4-2192568217710911]^

The Patchell study outlines the basic surgical selection criteria applied to most metastatic spine tumor patients: patients must be healthy enough to tolerate the intervention, they should have an expected survival over 3 to 6 months, and they must have some expectation of neurologic recovery. Refining the Patchell selection criteria by incorporating pathology-specific prognostic markers has the potential to improve surgical decision making.

A major consideration for surgical selection is anticipated survival. It is thought that patients should have an expected survival of 3 to 6 months to reap the benefits of the intervention. As survival in MPCS is dependent on tumor responsivity to treatment, patients with hormone-naive tumors have a significant survival advantage over patients with hormone-refractory tumors. Of importance, both hormone-naive and hormone-refractory patients have an expected survival of over 6 months. Similarly, although PSA, Gleason score, and KPS scores demonstrate a statistically and temporally significant difference in survival, no marker definitively demonstrates a survival below the expected criteria of 3 to 6 months. This must be interpreted with caution, as expected survival is borderline, the strength of studies is insufficient, and none discuss prognostic markers in combination. It is possible that multiple negative prognostic indicators may predictably shorten survival to a degree that decompressive surgery will not offer a satisfactory result. However, we found no prognostic marker that definitively rules out MPCS patients from having surgery.

Additionally, the tenet that patients should have a 3- to 6-month anticipated survival may be flawed. Less invasive options than the 360-degree decompression Patchell advocated, including "separation surgery"^[@bibr52-2192568217710911]^ and minimally invasive surgical techniques,^[@bibr53-2192568217710911],[@bibr54-2192568217710911]^ may produce similar results with less morbidity and convalescence, potentially expanding surgical indications to patients with shorter anticipated survival. Also, Patchell focused on neurologic deficit, yet local and mechanical pain can limit mobility and quality of life. Less invasive options such as percutaneous fixation and vertebral augmentation may be useful palliative options in patients with limited life expectancy.

Evidence supports the use of vertebral augmentation in the treatment of metastatic disease and is agreed upon by expert consensus. Although excluded from this study, 4 mixed-histology Level 4 retrospective cohorts reported sustained analgesia in over 80% of patients with minimal complications.^[@bibr55-2192568217710911][@bibr56-2192568217710911][@bibr57-2192568217710911]--[@bibr58-2192568217710911]^ In 2 studies, functional status improved due to increased mobility from pain relief.^[@bibr57-2192568217710911],[@bibr58-2192568217710911]^ Prostate cancer usually causes sclerotic lesions until late in the disease, often once the patient has hormonal-resistant cancer, when osteolytic lesions occur.^[@bibr59-2192568217710911],[@bibr60-2192568217710911]^ Thus, vertebral augmentation may be most useful in patients with advanced disease.

Predictability of postoperative functional status is outlined by our study. The majority of patients were ambulatory postoperatively, and approximately 50% of nonambulatory patients regain the ability to walk. Operative selection criteria were poorly outlined, however, including the preoperative ambulatory status and temporal course of neurologic decline. In our pooled data, only one Frankel Class B patient had a good outcome (Class D or E), although good outcomes occurred in the majority of patients with preoperative Class C, D, or E function. Selection bias is noted in this combined cohort, however, as most cases were Class C and D. More complicated is data about urinary continence. Although almost 50% of patients regained continence following surgery, this information must be approached with caution as incontinence may be a direct result of the disease process and treatment in prostate cancer and not spinal cord compression. Surgical treatment provided significant pain relief. In 2 studies, 74% of patients noted significant pain relief,^[@bibr41-2192568217710911],[@bibr42-2192568217710911]^ and 2 separate studies demonstrated a large reduction in narcotic medication requirements.^[@bibr3-2192568217710911],[@bibr4-2192568217710911]^ Thus, surgical treatment reliably improves/maintains motor function, may allow well-selected patients to regain ambulation and urinary continence, and can reduce the pain of spinal metastases.

Finally, patients must be able to medically tolerate decompressive surgery. The included studies had a 20% perioperative morbidity and 10% mortality. Anecdotally, Iacovou notes that hormone-refractory patients recovered from surgery more slowly; but no further information is available.^[@bibr42-2192568217710911]^ Ju notes that extent of surgery (number of levels) and age were significant predictors of surgical complications.^[@bibr3-2192568217710911]^ Although this information is consistent between studies, the surgical techniques are dated. All of the studies include large numbers of laminectomy-only patients, while the more contemporary 360-degree decompressive procedure is underrepresented making it difficult to apply contemporaneously. That said, as a predominantly osteoblastic tumor, laminectomy alone may be viable as the structural integrity of the affected vertebral body may not be compromised. Additionally, prostate cancer has a predilection for the lumbar spine,^[@bibr61-2192568217710911]^ resulting in cauda equina as opposed to spinal cord compression, making Patchell less relevant. This underscores the importance of histologically specific studies on spine metastases.

Surgical treatment of prostate metastasis to the spine has the potential to reliably decrease pain, maintain or improve ambulation, and maintain urinary continence. Systematic review of the literature is limited and the strength of data relatively poor; however, there is no definitive marker that would preclude consideration for surgery. Despite these limitations, this review does provide prostate cancer--specific data that will enable improved shared decision making for patients presenting with symptomatic spinal metastasis. Further high-quality prospective studies on this important topic are warranted.

Conclusion {#section15-2192568217710911}
==========

There is a dearth of literature on the treatment of prostate metastases to the spine. All studies have a level of evidence of IV, and consistencies across studies correspond to the more robust mixed-histology literature. The overall results of the original questions are the following:**Question 1:** The overall survival and functional outcome of surgery for prostate metastases of the spine were delineated.**Question 2:** Literature supports only 2 patient factors may influence postoperative survival and may, therefore, influence surgical decision making: (1) there is low strength of evidence for the impact of hormonal naivety on survival and (2) low strength of evidence for the impact of preoperative KPS score. Experts agree that both factors are important.**Question 3:** There is insufficient evidence to determine the effect of the evolution of operative techniques on outcome. Despite this absence, experts believe in the utility of modern techniques such as circumferential decompression and reconstruction and more limited procedures such as vertebral augmentation.
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